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Introduction 
 
Methotrexate (MTX) is an antimetabolite with 
activity against a wide variety of malignancies. 
High dose MTX (HDMTX), defined as a MTX dose 
greater than 500 mg/m2, is used in the treat-
ment of lymphoid malignancies and osteosarco-
mas. MTX is excreted 90% unchanged in the 
urine. The safe use of HDMTX requires ade-
quate elimination of drug, monitoring of MTX 
concentrations and the use of a leucovorin res-
cue. End stage renal disease (ESRD) has been 
viewed as a contraindication to MTX therapy 
due to an increased incidence of serious ad-
verse events [1, 2].  
 
Materials and methods 
 
Submission of this case report was approved by 
the human research ethics committee 
(reference number HREC/11/QPAH/478). It 
discusses the case of a 52 year old female with 
post-transplant lymphoproliferative disorder 
(PTLD), primary central nervous system lym-
phoma (PCNSL), which was managed with 
HDMTX in the context of ESRD. She had previ-
ously undergone a heart-lung transplant for se-
vere pulmonary hypertension due to recurrent 
pulmonary emboli complicating essential throm-
bocythemia. Post-transplant, she developed 
calcineurin inhibitor induced ESRD and was 
commenced on hemodialysis. She also required 
a jejunostomy feeding tube and experienced 
chronic diarrhoea following a transplant-related 
vagal injury. Five years post-transplant, the pa-
tient presented with a left upper limb mo-
noparesis and partial seizures. An MRI brain 
revealed several space occupying lesions, bi-
opsy of which was consistent with Epstein-Barr 
virus positive monomorphic B-cell PTLD 
(subtype diffuse large B-cell lymphoma). Staging 
did not reveal any other disease sites. Her ECOG 
performance status was 2. Immunosuppressive 
therapy was reduced. Following discussions 
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between the treating teams and patient, she 
commenced treatment with a regimen including 
HDMTX supported by extended hours, high-flux 
hemodialysis.  
 
Treatment consisted of HDMTX (1g/m2; total 
dose 1600mg) administered as an intravenous 
(IV) infusion over 2 hours every two weeks, fol-
lowed by extended hours high-flux hemodialysis 
(Figure 1). At each dialysis session a Fresenius 
FX80 synthetic high-flux membrane (Fresenius 
Inc., Walnut Creek, CA) was used with a blood 
flow rate of 250 ml/min and a dialysate flow 
rate of 500 ml/min. Plasma MTX concentrations 
were measured using a Fluorescence Polariza-
tion Radioimmunoassay (Abbott Laboratories, 
Abbott Park, IL) according to manufacturer’s 
instructions (Figure 1). Leucovorin rescue 
commenced with a dose of 60mg IV 12 
hours after completion of the MTX infu-
sion followed by 50mg IV q6h × 2, then 
200mg IV q4h × 12 doses after the first 
dose of HDMTX and 50mg IV q6h × 15, 
then 200mg IV q6h × 10 doses after the 
second dose. In addition to HDMTX, the 
patient’s treatment included dexa-
methasone, rituximab 375mg/m2 IV 
weekly × 8 and intrathecal cytarabine 
100mg. Subsequently, when further mye-
losuppressive chemotherapy was pre-
cluded by infection, EBV specific T-cell 
therapy and whole brain irradiation (30Gy 
in 10 fractions) was administered [3]. 
 
Results 
 
The patient tolerated the first dose of 
HDMTX well apart from worsening of her 
pre-existing anemia and mild transient 
transaminase elevation. Greater toxicity 
was noted following the second dose. 
The patient developed neutropenia 
(neutrophil count nadir 0.29 × 109/L) 
which resolved following two doses of 
granulocyte colony stimulating factor, 
transient worsening of pre-existing throm-
bocytopenia (platelet count nadir 34 × 
109/L) and ongoing anemia. Her pre-
existing diarrhoea worsened necessitat-
ing treatment with an octreotide infusion. 
In addition, she again experienced mild 
transient transaminase elevation plus 
nausea and oral mucositis that re-
sponded to symptomatic management. 
She also suffered from a urinary tract 
infection and an enterococcus fecalis 
infection of her arteriovenous fistula, which was 
complicated by aortic valve endocarditis. She 
was treated with broad spectrum antibiotics and 
made a complete recovery.  
Unfortunately the patient died approximately 
four months following her second dose of 
HDMTX from a cytomegalovirus (CMV)-related 
perforated gastric ulcer. CMV infection had pre-
ceded her diagnosis of PTLD. A post mortem 
examination showed that she was in complete 
remission with no evidence of lymphoma.  
 
Discussion 
 
This case discusses the use of HDMTX in a pa-
tient with ESRD with the support of high-flux 
hemodialysis, MTX concentration monitoring 
Figure 1. Plasma MTX concentrations following dose 1 (A) and 
dose 2 (B) of HDMTX in a logarithmic scale. Time 0 indicates 
the start of the 2 hour MTX infusion. The arrows indicate the 
high-flux hemodialysis sessions [an extended hours session (7 
hours first dose; 9 hours second dose) commencing 1 hour 
following completion of the MTX infusion, followed by 4 daily 4-
6 hour sessions]. 
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and leucovorin rescue. The use of MTX in ESRD 
is controversial with the literature describing 
prolonged severe toxicity and increased mortal-
ity following low dose MTX [1, 2]. While HDMTX 
has traditionally been avoided in patients with 
ESRD, it is documented that patients with de-
layed MTX excretion due to HDMTX induced 
acute renal failure (ARF) experience substantial 
morbidity and mortality [4-6]. However, HDMTX 
has a critical role in the management of PCNSL 
with several studies demonstrating the superior-
ity of HDMTX over radiation alone and of chemo-
therapy regimens containing HDMTX over those 
which do not [7-12]. Therefore, in order to treat 
the described patient optimally, HDMTX needed 
to be included in the regimen. HDMTX is also 
used in the curative treatment of acute lym-
phoblastic leukemia, Burkitt’s lymphoma and 
childhood osteosarcoma. Furthermore, while 
the use of intensive hydration and alkalinisation 
of the urine has substantially reduced the risk 
of ARF following HDMTX, it still occasionally oc-
curs [4, 6, 7, 13]. The use of optimal techniques 
to clear MTX in this scenario is essential to 
avoid a fatal outcome. 
 
Both standard intermittent hemodialysis and 
peritoneal dialysis have limited effectiveness in 
reducing plasma MTX concentrations due to its 
moderate (50%) plasma protein binding and 
large volume of distribution (0.76 L/kg), such 
that rebound increases of MTX concentrations 
post-dialysis have been reported, particularly 
following shorter dialysis sessions [6, 14, 15]. 
The effective use of repeated prolonged hemo-
dialysis and charcoal hemoperfusion in the 
management of a patient who developed ARF 
and very high MTX concentrations following 
HDMTX has been described, with the patient 
avoiding significant toxicity [13]. High-flux hemo-
dialysis has been successfully used to avoid 
toxicity in the management of three pediatric 
patients who developed post-HDMTX ARF, two 
of whom also received carboxypeptidase G2 
(glucarpidase) [16]. Two previous reports have 
described the effective use of high-flux hemodi-
alysis in patients with pre-existing ESRD. Mura-
shima et al describe the case of a patient with 
cerebral lymphoma who received HDMTX with-
out significant toxicity with the support of high-
flux hemodialysis [17]. In the same patient, the 
use of continuous multiple exchange peritoneal 
dialysis achieved lower clearance of MTX, but 
also prevented toxicity. A report from the M.D. 
Anderson described the effective clearance of 
MTX in six patients with high-flux hemodialysis 
[18].  
 
Alternative approaches to dialysis in the man-
agement of high MTX concentrations complicat-
ing HDMTX induced ARF have been investi-
gated, the most promising of which is glucarpi-
dase, which rapidly metabolises circulating MTX 
to an inactive metabolite. Glucarpidase is not 
commercially available, but has been used on a 
compassionate basis. Reported case series of 
these patients indicate that the administration 
of glucarpidase rapidly reduces MTX concentra-
tions, although does not completely prevent 
toxicity and deaths still occur, especially if ad-
ministration is delayed [6, 19]. There have been 
no reports of its use to facilitate the delivery of 
HDMTX in patients with pre-existing ESRD. 
 
With the support of high-flux hemodialysis, our 
patient was able to receive two doses of 
HDMTX. The toxicities directly attributable to 
MTX were limited, easily managed and reversi-
ble. More toxicity was observed following the 
second dose than the first. While the frequency 
and severity of abnormal transaminases relates 
to number of doses received [20], no such trend 
has been observed for mucositis or hematologi-
cal toxicity [21]. Possible reasons for the greater 
mucositis and hematological toxicity observed 
following the second dose include the lower 
dose of leucovorin given in the first 48 hours, 
longer time to complete clearance of MTX,  
more severe hypoalbuminemia and the pres-
ence of infection [22, 23]. The infectious com-
plications seen in the second cycle preceded, 
and may have contributed to, the brief episode 
of neutropenia. They occurred in the context of 
a patient who had substantial co-morbidities 
and multiple other risk factors for infection, in-
cluding post-transplant immunosuppressive 
therapy, ESRD, dexamethasone, rituximab and 
the presence of a central venous catheter and 
ateriovenous fistula. The patient’s immunosup-
pressive state also substantially contributed to 
her cause of death. It is likely that the use of 
HDMTX played a role in the achievement of the 
complete pathologic response observed at au-
topsy.  
 
This case adds to the limited literature showing 
that intensive high-flux hemodialysis can effec-
tively clear MTX in patients with ESRD. While 
these patients may have other co-morbidities 
which limit their tolerance of aggressive ther-
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apy, ESRD is not an absolute contraindication to 
the use of HDMTX when required for curative 
therapy of malignancy.  
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